Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.

Journal of Korean medical science - 1 Oct 2004

Lee Soo-Youn, Ki Chang-Seok, Hong Kyung Sue, Kim Jong Won

Abstract excerpt

We present a case with decreased metabolic activity of CYP2D6, a cytochrome P450 enzyme catalyzing the metabolism of nortriptyline (NT). Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B. This case suggests the clinical usefulness of pharmacogenetic testing in individualized dosage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Tricyclic
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Depression

Share to Genotype

Source

Open in PubMed Open full text

Identifiers

PMID: 15483356
DOI: 10.3346/jkms.2004.19.5.750
PMCID: PMC2816343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.PMID 15483356Read ↗

Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetineSemantic proximity Read ↗

The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.Semantic proximity Read ↗

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.Semantic proximity Read ↗

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.Semantic proximity Read ↗

Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype.Semantic proximity Read ↗

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.Semantic proximity Read ↗

Sequence-based CYP2D6 genotyping in the Korean population.Semantic proximity Read ↗

Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.Semantic proximity Read ↗

Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report.Semantic proximity Read ↗

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.Semantic proximity Read ↗

Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.Semantic proximity Read ↗

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.